Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Ascendis Pharma. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Ascendis Pharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
Ascendis Pharma's earnings are expected to grow by 17.2% yearly, however this is not considered high growth (20% yearly).
Ascendis Pharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Ascendis Pharma's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Jan Møller Mikkelsen serves as the Chief Executive Officer, President, Executive Director and Member of Executive Board of Ascendis Pharma A/S since December 2007. Mr. Mikkelsen served as Chief Executive Officer and President at Veloxis Pharmaceuticals A/S until August 2006. He served as President of Maxygen's Protein Pharma Division and Managing Director of Maxygen APS. In this capacity, he was responsible for an organization of about 80 people and 15 drug discovery and development projects. He Co-Founded ProFound Pharma A/S and served as its Co-Chief Executive Officer from 1999 to 2000. Mr. Mikkelsen served as Managing Director of Maxygen ApS. From 1989 to 1999, he served at Novo Nordisk A/S in various positions, including Director of Protein Discovery, heading a multinational organization of more than 150 people and was a member of enzyme research management. Mr. Mikkelsen serves as Chairman of HyScite Discovery. He serves as Director of Ascendis Pharma A/S since December 2007 and served as a Director of Nuevolution A/S. Mr. Mikkelsen served as Member of Advisory Team at Nordic Biotech. He holds an M.Sc. in Biochemistry from the University of Odense.
Insufficient data for Jan to compare compensation growth.
Insufficient data for Jan to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Ascendis Pharma management team is about average.
CFO, Senior VP & Member of Executive Board
VP of Finance & Principal Accounting Officer
Chief Administrative Officer & Senior VP
Head of Global Communications
Senior Vice President of Product Supply
Senior VP & Chief Medical Officer
Senior VP and Head of Innovation & Research
Senior VP & Chief Commercial Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Ascendis Pharma board of directors is about average.
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.